Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

NCT03283826 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

134

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated as primary endpoint was not achieved

Conditions

Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions

BIOLOGICAL: ATA188
DRUG: Placebo

Sponsor

Atara Biotherapeutics